Results 21 to 30 of about 51,890 (248)

Extracellular Vesicles in Hematological Malignancies: From Biomarkers to Therapeutic Tools

Diagnostics, 2020
Small extracellular vesicles (EVs) are a heterogenous group of lipid particles released by all cell types in physiological and pathological states.
Jihane Khalife, James F. Sanchez, Flavia Pichiorri   +2 more
doaj   +1 more source

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial [PDF]

, 2021
Background In a phase lb study, intravenous daratumumab plus pomalidomide and dexamethasone induced a very good partial response or better rate of 42% and was well tolerated in patients with heavily pretreated multiple myeloma.
Schecter, Jordan M, Moreau, Philippe, Schecter, Jordan M., Terpos, Evangelos, Mateos, Maria Victoria, Bila, Jelena, Boccadoro, Mario, Orfanidis, Ioannis, Mateos, Maria-Victoria, Sonneveld, Pieter, Delimpasi, Sosana, Dimopoulos, Meletios A., Katodritou, Eirini, Dimopoulos, Meletios A, Kampfenkel, Tobias, Symeonidis, Argiris, Vermeulen, Jessica, Qiu, Yanping, Baldini, Luca, Amin, Himal, Ukropec, Jon, BEKSAÇ, MERAL, Ahmadi, Tahamtan, Oriol, Albert, Carson, Robin, Einsele, Hermann   +25 more
core   +1 more source

Blood stem cell collections after mobilization with combination chemotherapy containing ifosfamide followed by G-CSF in multiple myeloma [PDF]

, 2003
High-dose chemotherapy with autologous peripheral blood stem cell transplantation is the standard treatment of patients with multiple myeloma today. In this study we used a combination mobilizing chemotherapy containing ifosfamide with G-CSF before stem ...
Werding, N., Straka, C., Adler-Reichel, S., Emmerich, B., Einsele, H., Hebart, H.   +5 more
core   +1 more source

Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today’s treat-to-target era

Experimental Hematology & Oncology, 2017
B cell lymphoma and multiple myeloma (MM) are the most common hematological malignancies which benefit from therapeutic monoclonal antibodies (mAbs)-based immunotherapies.
Li Zhang, Yu-Tzu Tai, Matthew Zhi Guang Ho, Lugui Qiu, Kenneth C. Anderson   +4 more
doaj   +1 more source

ML-based sequential analysis to assist selection between VMP and RD for newly diagnosed multiple myeloma

npj Precision Oncology, 2023
Optimal first-line treatment that enables deeper and longer remission is crucially important for newly diagnosed multiple myeloma (NDMM). In this study, we developed the machine learning (ML) models predicting overall survival (OS) or response of the ...
Sung-Soo Park, Jong Cheol Lee, Ja Min Byun, Gyucheol Choi, Kwan Hyun Kim, Sungwon Lim, David Dingli, Young-Woo Jeon, Seung-Ah Yahng, Seung-Hwan Shin, Chang-Ki Min, Jamin Koo   +11 more
doaj   +1 more source

Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma

Blood Cancer Journal, 2022
Chimeric antigen receptor T cells (CAR T) are groundbreaking therapies but may cause significant toxicities including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and cytopenias.
Kevin Charles Miller, Patrick Connor Johnson, Jeremy S. Abramson, Jacob D. Soumerai, Andrew J. Yee, Andrew R. Branagan, Elizabeth K. O’Donnell, Anna Saucier, Caron A. Jacobson, Matthew J. Frigault, Noopur S. Raje   +10 more
doaj   +1 more source

The Emerging Role of Extracellular Vesicle-Associated RNAs in the Multiple Myeloma Microenvironment

Frontiers in Oncology, 2021
Multiple myeloma (MM) is a cancer of terminally differentiated plasma cells (PCs) that develop at multiple sites within the bone marrow (BM). MM is treatable but rarely curable because of the frequent emergence of drug resistance and relapse.
Jihane Khalife, Jihane Khalife, James F. Sanchez, Flavia Pichiorri, Flavia Pichiorri   +4 more
doaj   +1 more source

Direct-to-patient research: Opportunity brings challenges

Cancer Treatment and Research Communications
Direct-to-patient (DTP) research offers promising alternatives to traditional models, potentially improving population-level data collection to understand disease initiation, progression, and response to treatment.
Anne Quinn-Young, Michael Andreini, Arianna Haynes, Niccolo Pabustan, Jessica Schulman, Mercedes Martillo, Katie Wozniak, Hearn Jay Cho, George Mulligan   +8 more
doaj   +1 more source

Widespread intronic polyadenylation diversifies immune cell transcriptomes

Nature Communications, 2018
Recognition of intronic polyadenylation (IpA) signals can lead to expression of truncated proteins lacking C terminal domains. Analysis of 3ʹ -seq and RNA-seq shows that IpA is widespread in circulating immune cells, while multiple myeloma cells show ...
Irtisha Singh, Shih-Han Lee, Adam S. Sperling, Mehmet K. Samur, Yu-Tzu Tai, Mariateresa Fulciniti, Nikhil C. Munshi, Christine Mayr, Christina S. Leslie   +8 more
doaj   +1 more source

Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury

Blood Advances
: Cast nephropathy is the most common cause of acute kidney injury (AKI) in patients with multiple myeloma (MM). A prompt reversal of renal injury is paramount for improving clinical outcomes.
E. Bridget Kim, Jack E. Malespini, Matthew Lei, Samuel S. Han, Cole W. Minsky, Andrew R. Branagan, Elizabeth K. O’Donnell, Diana Cirstea, Noopur S. Raje, Andrew J. Yee   +9 more
doaj   +1 more source